Global Uterine Fibroid Treatment Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Uterine Fibroid Treatment Drugs Market is presumed to reach the market size of nearly USD 5.63 BN by 2030 from USD 2.29 BN in 2022 with a CAGR of 11.9% under the study period 2023 - 2030.

Uterine fibroid treatment drugs are medications prescribed to manage the symptoms of uterine fibroids, which are growths or tumors (non-cancerous) that develop in the wall of the uterus. These drugs are typically used when surgery is not immediately necessary or when a less invasive approach is preferred. These can cause heavy menstrual bleeding, pelvic pain, and pressure, and the goal of these medications is to alleviate these symptoms.

MARKET DYNAMICS:

The Uterine fibroid treatment drugs market is driven by several factors reflecting the prevalence and impact of uterine fibroids on women's health. Uterine fibroids are a common gynecological condition, leading to a consistent demand for medications to manage associated symptoms. Heavy menstrual bleeding, pelvic pain, and pressure are common symptoms that drive patients to seek pharmaceutical interventions enhancing their quality of life. Non-surgical treatment options are preferred by many women to avoid the potential risks and recovery associated with surgery. Uterine fibroid treatment drugs offer a less invasive alternative. Additionally, some women with fibroids aim to preserve fertility, making uterine-sparing medications an appealing choice. Ongoing advancements in drug development and increasing patient awareness contribute to the expanding range of available treatment options. Clinical guidelines and the desire to minimize blood loss, a common symptom of fibroids, further support the use of these medications. Uterine fibroid treatment drugs also play a role in personalized medicine, allowing tailored treatment plans to address individual patient needs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of uterine fibroid treatment drugs. The growth and trends of uterine fibroid treatment drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the uterine fibroid treatment drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Gonadotropin-Releasing Hormone (GnRH) Agonists
Gonadotropin-Releasing Hormone (GnRH) Antagonists
Progestin-Releasing Intrauterine Device (IUD) & Contraceptives
Non-Hormonal Medications
Others

By Type

Subserosal Fibroids
Intramural Fibroids
Submucosal Fibroids
Pedunculated Fibroids

By End-User

Hospital Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Uterine Fibroid Treatment Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Uterine Fibroid Treatment Drugs market include Myovant Sciences GmbH, Pfizer Inc., Abbvie Inc, Ferring B.V., AstraZeneca, Bayer AG, Amring Pharmaceuticals Inc., Watson Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112112210

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . UTERINE FIBROID TREATMENT DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Gonadotropin-Releasing Hormone (GnRH) Agonists Historic and Forecast Sales by Regions
5.5 Gonadotropin-Releasing Hormone (GnRH) Antagonists Historic and Forecast Sales by Regions
5.6 Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Historic and Forecast Sales by Regions
5.7 Non-Hormonal Medications Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Subserosal Fibroids Historic and Forecast Sales by Regions
6.5 Intramural Fibroids Historic and Forecast Sales by Regions
6.6 Submucosal Fibroids Historic and Forecast Sales by Regions
6.7 Pedunculated Fibroids Historic and Forecast Sales by Regions

7 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY END-USER

7.1 Overview by End-User
7.2 Historical and Forecast Data
7.3 Analysis by End-User
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE UTERINE FIBROID TREATMENT DRUGS COMPANIES

9.1. Uterine Fibroid Treatment Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF UTERINE FIBROID TREATMENT DRUGS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Myovant Sciences GmbH
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Pfizer Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Abbvie Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Ferring B.V.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. AstraZeneca
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Bayer AG
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Amring Pharmaceuticals Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Watson Pharma Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies